[{"id":"0f520337-0cec-472e-b063-27456f36d835","acronym":"","url":"https://clinicaltrials.gov/study/NCT05351762","created_at":"2022-04-28T16:57:05.400Z","updated_at":"2024-07-02T16:36:07.840Z","phase":"Phase 2","brief_title":"Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC","source_id_and_acronym":"NCT05351762","lead_sponsor":"Xijing Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive • CDKN2A negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Aqupla (nedaplatin) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-07-04"},{"id":"e0ad898e-d8d7-42e6-a66f-cb759a7c10f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01040312","created_at":"2021-01-18T04:05:01.970Z","updated_at":"2024-07-02T16:36:59.371Z","phase":"","brief_title":"An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors","source_id_and_acronym":"NCT01040312","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • irinotecan • Aqupla (nedaplatin)"],"overall_status":"Completed","enrollment":" Enrollment 321","initiation":"Initiation: 10/15/2009","start_date":" 10/15/2009","primary_txt":" Primary completion: 09/29/2014","primary_completion_date":" 09/29/2014","study_txt":" Completion: 09/02/2015","study_completion_date":" 09/02/2015","last_update_posted":"2019-05-23"}]